Proof-of-Concept in Lead Target Indication Opens Up a $100 Billion Market Opportunity
Electrophysiology is one of the fastest-growing fields in medicine that is powered by innovations in advanced neural technologies. Autonomix is developing a precision-guided platform for nerve-sensing, ablation and verification – technology that sits at the core of an estimated $100 billion global market.
Given the significant unmet need, pancreatic cancer pain that originates from the Celiac Plexus nerve offers the most focused and cost-effective path to a potential approval. Autonomix’s early progress in this area underscores the platform’s potential to deliver meaningful relief for patients facing some of the most challenging forms of chronic and tumor-related pain.
Platform Expansion Opportunity Across High-Value Indications
Once validated, the Autonomix platform can extend to a broad range of conditions driven by overactive and dysfunctional nerves:
- Visceral and tumor-related pain
- Hypertension and other cardiovascular conditions
- Abdominal, joint, and lower back pain
- Pulmonary and digestive diseases
- Urinary tract disorders
- Additional organ-specific dysfunctions involving nerve signaling
Wherever the nervous system plays a role, Autonomix has the potential to make an impact. This broad applicability represents a major opportunity to improve patient outcomes and generate long-term value for stakeholders.
The Full Autonomix Market Opportunity
